Tocagen Inc (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Other equities analysts have also issued research reports about the company. Stifel Nicolaus assumed coverage on Tocagen in a research note on Monday, May 15th. They issued a “buy” rating and a $24.00 price target for the company. Leerink Swann assumed coverage on Tocagen in a research note on Monday, May 15th. They issued a “mkt perform” rating and a $19.00 price target for the company. Finally, Evercore ISI restated an “outperform” rating and issued a $28.00 price target on shares of Tocagen in a research note on Tuesday, May 9th.

Shares of Tocagen (TOCA) traded down 1.78% on Tuesday, reaching $13.22. The company’s stock had a trading volume of 27,660 shares. The company’s 50-day moving average is $11.26 and its 200 day moving average is $13.45. The company’s market capitalization is $261.88 million. Tocagen has a 12-month low of $9.68 and a 12-month high of $17.95.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.04. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Equities analysts anticipate that Tocagen will post ($2.51) earnings per share for the current fiscal year.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/tocagen-inc-toca-upgraded-to-hold-by-zacks-investment-research/1530214.html.

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. purchased a new stake in Tocagen during the second quarter valued at approximately $5,036,000. Northern Trust Corp purchased a new stake in Tocagen during the second quarter valued at approximately $1,201,000. Nicholas Investment Partners LP purchased a new stake in Tocagen during the second quarter valued at approximately $228,000. New York State Common Retirement Fund purchased a new stake in Tocagen during the second quarter valued at approximately $108,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in Tocagen during the second quarter valued at approximately $273,000. Institutional investors own 37.87% of the company’s stock.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.